SCHEMBL3247038

SCHEMBL3247038

CC(Cl)CNc1cnn(C)c(=O)c1Cl

nearest known ligand 0.65

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
KAT2B Q92831 13/20 0.65
BRD9 Q9H8M2 6/20 0.61
BRD4 O60885 9/20 0.59
BPTF Q12830 7/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3250048 0.79 KAT2B (0.63) KAT2BBRD9BRD4BPTF
SCHEMBL9982691 0.77 KDM4E (0.64) KAT2BBRD9BRD4BPTF
SCHEMBL7160804 0.73 KAT2B (0.74) KAT2BBRD9BRD4BPTF
SCHEMBL23682690 0.73 BRD4 (1.00) KAT2BBRD9BRD4BPTF
SCHEMBL27536539 0.71 KAT2B (0.65) KAT2BBRD9BRD4BPTF
SCHEMBL26910160 0.69 BPTF (1.00) KAT2BBRD9BRD4BPTF
SCHEMBL29569377 0.69 BPTF (1.00) KAT2BBRD9BRD4BPTF
SCHEMBL10366660 0.69 BPTF (0.50) KAT2BBRD9BRD4BPTF
SCHEMBL23682831 0.69 BPTF (1.00) KAT2BBRD9BRD4BPTF
SCHEMBL979278 0.68 KAT2B (0.60) KAT2BBRD9BRD4BPTF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1417206-B1 NOVEL 2H-PYRIDAZINE-3-ONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND A PROCESS FOR THE PREPARATION OF THE ACTIVE INGREDIENT EGIS GYOGYSZERGYAR NYRT (HU) 2010-05-05 EP disclosed
US-7183283-B2 Piperidinyl-alkylamino-pyridazinone derivatives, a process for the preparation thereof and pharmaceutical compositions containing said compounds EGIS GYOGYSZERGYAR RT. (HU) 2007-02-27 US disclosed
CN-1289495-C New piperidinyl-alkylamino-pyridazinone derivatives, a process for the preparation thereof and pharmaceutical compositions containing said compounds EGYT GYOGYSZERVEGYESZETI GYAR (HU) 2006-12-13 CN disclosed
US-7098210-B2 2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient EGIS Gyógyszergyár Rt. (HU) 2006-08-29 US disclosed
EP-1501823-B1 NEW PIPERIDINYL-ALKYLAMINO-PYRIDAZINONE DERIVATIVES, A PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS EGYT GYOGYSZERVEGYESZETI GYAR (HU) 2005-12-07 EP disclosed
US-20050215560-A1 Piperidinyl-alkylamino-pyridazinone derivatives, a process for the preparation thereof and pharmaceutical compositions containing said compounds EGIS GYOGYSZERGYAR RT. (HU) 2005-09-29 US disclosed
CN-1630652-A New piperidinyl-alkylamino-pyridazinone derivatives, a process for the preparation thereof and pharmaceutical compositions containing said compounds EGYT GYOGYSZERVEGYESZETI GYAR (HU) 2005-06-22 CN disclosed
EP-1501823-A1 NEW PIPERIDINYL-ALKYLAMINO-PYRIDAZINONE DERIVATIVES, A PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS EGIS GYOGYSZERGYAR RT. (HU) 2005-02-02 EP disclosed
US-20040171619-A1 Novel 2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient EGIS GYOGYSZERGYAR RT. (HU) 2004-09-02 US disclosed
EP-1417206-A1 NOVEL 2 i H /i -PYRIDAZINE-3-ONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND A PROCESS FOR THE PREPARATION OF THE ACTIVE INGREDIENT Egis Gyogyszergyar Rt. (HU) 2004-05-12 EP disclosed
WO-2003091244-A1 NEW PIPERIDINYL-ALKYLAMINO-PYRIDAZINONE DERIVATIVES, A PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS EGIS Gyógyszergyár Rt. (HU) 2003-11-06 WO disclosed
WO-2003010166-A1 NOVEL 2H-PYRIDAZINE-3-ONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND A PROCESS FOR THE PREPARATION OF THE ACTIVE INGREDIENT EGIS Gyógyszergyár Rt. (HU) 2003-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215560-A1 Piperidinyl-alkylamino-pyridazinone derivatives, a process for the preparation thereof and pharmaceutical compositions containing said compounds H1-0, HTR5A, H1-5 KAT2B 1267/4885BRD9 2635/4885BRD4 1671/4885
US-20040171619-A1 Novel 2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient HTR2C, HTR5A, HTR3C KAT2B 3579/4885BRD9 2928/4885BRD4 792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.